Amarin Past Earnings Performance
Past criteria checks 0/6
Amarin's earnings have been declining at an average annual rate of -19.3%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been declining at an average rate of 24.9% per year.
Key information
-19.32%
Earnings growth rate
-18.59%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | -24.94% |
| Return on equity | -7.48% |
| Net Margin | -15.51% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jun 22
AMRN: Guideline Endorsements Will Still Translate Into Weak Future Earnings
Analysts have kept their $12.50 price target on Amarin unchanged. They cited only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially alter their valuation view.Narrative Update • Jun 05
AMRN: Guideline Inclusion Will Still Lead To Persistent Revenue Pressure
Analysts kept their $12.50 price target for Amarin unchanged, citing only very small model tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially affect their overall valuation view. What's in the News Shareholders are scheduled to vote at the May 13, 2026 Annual General Meeting on adopting amended and restated articles of association, which would allow Amarin to send electronic notices of future Annual General Meetings via a website if approved.Narrative Update • May 21
AMRN: Guideline Support Will Not Prevent Future Revenue And Margin Pressure
Analysts have lifted their price target on Amarin stock by $0.50 to $12.50, citing updated assumptions around slightly lower expected revenue declines, a higher projected profit margin, a modestly reduced discount rate, and a lower future P/E multiple as the key drivers of the change. Analyst Commentary Recent commentary around Amarin’s updated price target highlights a mix of optimism on execution and ongoing caution on longer term growth and valuation risk.Narrative Update • Apr 24
AMRN: Guideline Endorsements And Execution Risks Will Limit Future Share Returns
Analysts have maintained their fair value estimate for Amarin at $12.00. They made only minor adjustments to assumptions such as the discount rate and future P/E, which resulted in no change to the updated price target.Narrative Update • Apr 08
AMRN: Guideline Support And Flat Earnings Outlook Will Restrain Future Upside
Narrative Update on Amarin Amarin's updated analyst price target holds steady at $12.00, as analysts point to only very small adjustments in discount rate, revenue growth assumptions, profit margin and future P/E that do not materially change their overall valuation view. Analyst Commentary Analysts covering Amarin are generally treating the current valuation as balanced, with the updated US$12.00 price target reflecting only modest tweaks to their core assumptions rather than a major shift in outlook.Narrative Update • Mar 25
AMRN: Guideline Tailwinds And Earnings Assumptions Will Limit Future Upside Potential
Amarin's updated analyst price target holds steady at $12.00, with analysts pointing to only marginal tweaks in the discount rate and long-term P/E assumptions as they refine their valuation framework rather than rethink the story. Analyst Commentary Analysts covering Amarin are keeping the updated US$12.00 target steady, framing recent tweaks as fine tuning of their models rather than a shift in the fundamental view on the company.Narrative Update • Mar 11
AMRN: Index Removal And Weaker Margins Will Restrict Future Upside Potential
Analysts have revised their price target on Amarin to $12.00, reflecting updated assumptions for revenue trends, profit margins, the discount rate, and a higher future P/E multiple in their models. Analyst Commentary Analysts revising their models for Amarin are focusing on how updated revenue and margin assumptions, along with the use of a higher P/E multiple, translate into the new US$12.00 price target.Narrative Update • Feb 25
AMRN: Index Removal And Execution Risks Will Limit Future Upside Potential
Analysts have modestly adjusted their price target on Amarin, keeping fair value around $12.00. Small tweaks to the discount rate and future P/E assumptions refine their view rather than signal a major shift in the story.Narrative Update • Feb 11
AMRN: Index Removal And Execution Risks Will Continue To Limit Upside
Analysts have adjusted their price target for Amarin to US$12.00. They attribute this move to slightly higher assumed discount rates, a modest tweak to long term revenue and margin expectations, and a small uplift in future P/E assumptions.Narrative Update • Jan 27
AMRN: Index Removal And Execution Risks Will Constrain Future Upside Potential
Analysts have reaffirmed Amarin's fair value at US$12.00 per share, citing only modest tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the stock. Analyst Commentary Analysts are largely using the reaffirmed US$12.00 fair value as a reference point to stress test their assumptions on growth, profitability and execution risk for Amarin, rather than to rethink the overall thesis.Narrative Update • Jan 12
AMRN: Index Removal And Weakening Revenue Outlook Will Constrain Future Upside Potential
Analysts have kept their fair value estimate for Amarin steady at US$12.00 per share, with only minor model tweaks to the discount rate, revenue trajectory and expected P/E that help to fine tune rather than shift their overall price target view. What's in the News Amarin issued revenue guidance for the fourth quarter of 2025, expecting net revenue of US$48 million to US$53 million, and for the full year 2025, expecting net revenue of US$212 million to US$217 million (corporate guidance).Analysis Article • Dec 10
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Narrative Update • Dec 10
AMRN: Pricing And Competitive Pressures Will Likely Limit Future Upside Potential
Analysts have modestly lifted their price target on Amarin to $12.00 from $12.00. This reflects steady assumptions around long term discount rates, revenue growth, profit margins, and future earnings multiples despite a still cautious backdrop for the broader sector.Narrative Update • Nov 26
AMRN: Rising Competitive Pressures Will Likely Challenge Future Profit Margin Expansion
Amarin's analyst price target has increased from $11.00 to $12.00. This reflects analysts' expectations of improved revenue growth and a notably stronger profit margin outlook for the company.Analysis Article • Oct 04
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a really impressive month, gaining 25% after a shaky period...Analysis Article • Jun 12
Amarin Corporation plc (NASDAQ:AMRN) Shares Fly 27% But Investors Aren't Buying For Growth
Amarin Corporation plc ( NASDAQ:AMRN ) shares have continued their recent momentum with a 27% gain in the last month...Analysis Article • Jun 12
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jun 06
Amarin Is A Sell Despite The Large Cash Balance
Summary Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with operating expenses exceeding product revenues, and European launches have not offset U.S. declines. Amarin trades below its cash value, providing some margin of safety and potential M&A appeal, but ongoing cash burn will erode this over time. Given the lack of clear catalysts and persistent losses, I expect Amarin to generate negative returns unless strategic action occurs soon. Read the full article on Seeking Alpha
New Narrative • Apr 01
I Foresee 49 Approvals Driving European And Global Market Expansion
Expanded regulatory approvals and commercialization in 49 markets support future revenue growth, particularly through focused expansion in Europe and worldwide.Analysis Article • Mar 15
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26%
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Jan 24
Amarin Corporation plc (NASDAQ:AMRN) Held Back By Insufficient Growth Even After Shares Climb 39%
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Jan 03
Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysis Article • Oct 29
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1x Amarin Corporation plc ( NASDAQ:AMRN ) is definitely a...Analysis Article • Aug 01
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amarin fair value estimate is US$0.53 Amarin's US$0.68 share...Analysis Article • Jun 06
Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
The Amarin Corporation plc ( NASDAQ:AMRN ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Apr 16
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Summary Amarin is going through a turbulent period with a strong contraction in revenue and margins. The EU and China markets seem too small to make significant changes, and the US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin is reducing. My share price evaluation does not seem to offer positive returns on investment. Read the full article on Seeking AlphaAnalysis Article • Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Amarin Corporation plc ( NASDAQ:AMRN ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Jan 15
Amarin: Sarissa Is Giving Me Hope Again
Summary Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future. Read the full article on Seeking AlphaAnalysis Article • Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Current share...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Amarin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 217 | -34 | 100 | 19 |
| 31 Dec 25 | 214 | -39 | 115 | 20 |
| 30 Sep 25 | 227 | -86 | 132 | 20 |
| 30 Jun 25 | 219 | -104 | 149 | 21 |
| 31 Mar 25 | 214 | -88 | 149 | 21 |
| 31 Dec 24 | 229 | -82 | 152 | 21 |
| 30 Sep 24 | 241 | -39 | 159 | 21 |
| 30 Jun 24 | 265 | -34 | 168 | 21 |
| 31 Mar 24 | 277 | -53 | 180 | 22 |
| 31 Dec 23 | 307 | -59 | 200 | 22 |
| 30 Sep 23 | 322 | -52 | 224 | 22 |
| 30 Jun 23 | 346 | -38 | 237 | 22 |
| 31 Mar 23 | 361 | -91 | 273 | 26 |
| 31 Dec 22 | 369 | -106 | 304 | 30 |
| 30 Sep 22 | 423 | -92 | 329 | 31 |
| 30 Jun 22 | 476 | -100 | 373 | 33 |
| 31 Mar 22 | 536 | -22 | 393 | 30 |
| 31 Dec 21 | 583 | 8 | 408 | 29 |
| 30 Sep 21 | 606 | -2 | 433 | 32 |
| 30 Jun 21 | 620 | 4 | 450 | 34 |
| 31 Mar 21 | 601 | 1 | 435 | 38 |
| 31 Dec 20 | 614 | -18 | 463 | 39 |
| 30 Sep 20 | 590 | -16 | 443 | 42 |
| 30 Jun 20 | 546 | -13 | 405 | 40 |
| 31 Mar 20 | 511 | -19 | 386 | 37 |
| 31 Dec 19 | 430 | -23 | 324 | 34 |
| 30 Sep 19 | 364 | -63 | 307 | 35 |
| 30 Jun 19 | 307 | -84 | 275 | 40 |
| 31 Mar 19 | 259 | -117 | 255 | 51 |
| 31 Dec 18 | 229 | -116 | 227 | 56 |
| 30 Sep 18 | 206 | -105 | 183 | 56 |
| 30 Jun 18 | 198 | -92 | 166 | 53 |
| 31 Mar 18 | 190 | -71 | 144 | 48 |
| 31 Dec 17 | 181 | -68 | 135 | 47 |
| 30 Sep 17 | 166 | -73 | 130 | 45 |
| 30 Jun 17 | 151 | -78 | 123 | 48 |
| 31 Mar 17 | 139 | -78 | 118 | 47 |
| 31 Dec 16 | 130 | -86 | 111 | 50 |
| 30 Sep 16 | 118 | -81 | 104 | 53 |
| 30 Jun 16 | 107 | -97 | 104 | 53 |
| 31 Mar 16 | 91 | -147 | 104 | 52 |
| 31 Dec 15 | 82 | -149 | 101 | 51 |
| 30 Sep 15 | 72 | -147 | 96 | 50 |
| 30 Jun 15 | 64 | -141 | 88 | 52 |
Quality Earnings: AMRN is currently unprofitable.
Growing Profit Margin: AMRN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMRN is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare AMRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: AMRN has a negative Return on Equity (-7.48%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/25 22:26 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amarin Corporation plc is covered by 19 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Andrew Fein | Chardan Capital Markets, LLC |
| John Boris | Citigroup Inc |